Stockreport

Biodesix Announces First Quarter 2024 Results Driven by Growth in Lung Diagnostic Testing for Lung Nodule Management [Yahoo! Finance]

Biodesix, Inc.  (BDSX) 
PDF First quarter 2024 gross profit margin of 79% versus 65% for the first quarter 2023 and 77% for the fourth quarter of 2023; Raised $55 million in gross proceeds from [Read more]